Pliant Therapeutics Inc (NASDAQ: PLRX) kicked off On Friday, up 8.22% from the previous trading day, before settling in for the closing price of $1.46. Over the past 52 weeks, PLRX has traded in a range of $1.10-$16.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -78.30% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 28.84%. With a float of $54.04 million, this company’s outstanding shares have now reached $61.39 million.
In an organization with 171 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Pliant Therapeutics Inc (PLRX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Pliant Therapeutics Inc is 11.97%, while institutional ownership is 86.76%. The most recent insider transaction that took place on Jan 17 ’25, was worth 587,150. In this transaction President and CEO of this company sold 52,419 shares at a rate of $11.20, taking the stock ownership to the 430,517 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Financial Officer sold 20,148 for $11.20, making the entire transaction worth $225,680. This insider now owns 262,608 shares in total.
Pliant Therapeutics Inc (PLRX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 28.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 31.14% during the next five years compared to -78.30% drop over the previous five years of trading.
Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators
Take a look at Pliant Therapeutics Inc’s (PLRX) current performance indicators. Last quarter, stock had a quick ratio of 11.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.61, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -1.91 in one year’s time.
Technical Analysis of Pliant Therapeutics Inc (PLRX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.85 million. That was inferior than the volume of 1.78 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 48.10%.
During the past 100 days, Pliant Therapeutics Inc’s (PLRX) raw stochastic average was set at 71.11%, which indicates a significant decrease from 80.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1112 in the past 14 days, which was lower than the 0.1133 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4034, while its 200-day Moving Average is $6.2748. However, in the short run, Pliant Therapeutics Inc’s stock first resistance to watch stands at $1.6674. Second resistance stands at $1.7549. The third major resistance level sits at $1.8647. If the price goes on to break the first support level at $1.4701, it is likely to go to the next support level at $1.3603. The third support level lies at $1.2728 if the price breaches the second support level.
Pliant Therapeutics Inc (NASDAQ: PLRX) Key Stats
The company with the Market Capitalisation of 96.99 million has total of 61,386K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -210,300 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -56,170 K.
